So, why has everyone in U.S. government covered up this vaccine? Crucell is developing an Ebola vaccine in collaboration with the Vaccine Research Center (VRC) of the NIH National Institute of Allergy and Infectious Diseases (NIAID). It has been shown to completely protect monkeys against the virus with a single dose of the vaccine. Under the terms of the agreement with VRC, Crucell has an option for exclusive worldwide commercialization rights to the Ebola vaccine. Crucell’s Ebola vaccine entered Phase I clinical trials in 2006. Two groups of 16 volunteers were enrolled and vaccinated. The study showed safety and immunogenicity at the doses evaluated. In October 2008, Crucell secured a NIAID/NIH award to advance the development of Ebola and Marburg vaccines, with the ultimate aim of developing a multivalent filovirus vaccine. The award provides funding of up to $30 million, with additional options, worth a further $40 million. https://youtube/watch?v=FvwSkuQWzI8
Posted on: Thu, 23 Oct 2014 19:54:13 +0000
Trending Topics
Recently Viewed Topics
© 2015